|
WO2021030196A1
|
|
Elp fusion proteins comprising parathyroid hormone for controlled and sustained release
|
|
US2020392112A1
|
|
Metalloenzyme inhibitor compounds
|
|
CA3113654A1
|
|
Methods of reversing ticagrelor activity
|
|
AU2017387033A1
|
|
Metalloenzyme inhibitor compounds
|
|
CN109310641A
|
|
For controlled and sustained release ELP fusion protein
|
|
CN107427556A
|
|
For treating the method and composition of muscle disease and illness
|
|
CN107206044A
|
|
For controlled and sustained release ELP fusion proteins
|
|
US2017182130A1
|
|
Methods and compositions for treating cystic fibrosis
|
|
US2015361154A1
|
|
Therapeutic agents, compositions, and methods for glycemic control
|
|
US2015290328A1
|
|
Formulations of active agents for sustained release
|
|
AU2013224720A1
|
|
Fusion peptide therapeutic compositions
|
|
EP2785367A1
|
|
Therapeutic agents comprising insulin amino acid sequences
|
|
CN104023784A
|
|
Formulations of active agents for sustained release
|
|
WO2013003449A2
|
|
Methods of treatment with glp-1 receptor agonists
|
|
CA2873553A1
|
|
Use of modified vasoactive intestinal peptides in the treatment of hypertension
|
|
CA2804755A1
|
|
Modified vasoactive intestinal peptides
|
|
WO2010080578A1
|
|
Biologically active proteins activatable by peptidase
|
|
WO2010014689A1
|
|
Pharmaceutical formulations comprising elastin-like proteins
|
|
US2008032400A1
|
|
Multimeric ELP fusion constructs
|
